Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
RedHill Biopharma (NASDAQ: RDHL) announced Tuesday September 1, 2026 an exclusive global commercialization license for Rebyota (fecal microbiota, live-jslm) and an exclusive U.S. commercialization license for Clenpiq (sodium picosulfate, magnesium oxide, and citric acid oral solution for colonoscopy bowel preparation) from Ferring Pharmaceuticals, for an upfront payment of $12 million plus tiered royalties on net sales and potential milestones. Rebyota is the first-in-class FDA-approved microbiota-based therapy for the prevention of recurrent Clostridioides difficile infection in adults 18+ following antibiotic treatment (approved November 2022), generating approximately $16.9 million in 2025 U.S. net sales. The two products collectively generated approximately $37.5 million in 2025 U.S. net sales. Ferring retains Rebyota manufacturing and continues supply under the agreement. Not a peptide, but the transaction matters for the peptide-microbiome intersection: RedHill's expanded GI franchise now anchors the microbiome-therapy category alongside Vedanta's VE303, Seres Therapeutics' VOWST/SER-109, and the emerging peptide-antimicrobial and postbiotic categories.
The Samsung Biologics tender offer for PolyPeptide Group AG (announced July 20 at CHF 44.31 per share, CHF 1.46 billion / $1.8 billion) entered its 10 SIX Swiss Exchange trading-day cooling-off period Tuesday September 1, 2026 following the Monday August 31 publication of the formal tender offer prospectus by Samsung's Swiss subsidiary Samsung Peptide AG. The main offer period commences Tuesday September 15 and runs through October 12, 2026 at 4 p.m. Swiss time. Closing conditions include a 66⅔% minimum acceptance threshold plus customary regulatory approvals. Draupnir Holding B.V. (approximately 55.65% of PolyPeptide shares outstanding) has already committed to tender all of its shares. Transaction close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide from SIX, integrating the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into Samsung's Incheon multi-modality footprint alongside the existing monoclonal antibody and antibody-drug conjugate operations.
Roche (SIX: ROG) is scheduled to hold its investor Pharma Day Monday September 28, 2026, providing updates across the R&D portfolio including three obesity assets that collectively position the company as the credible third-place global obesity competitor behind Eli Lilly and Novo Nordisk. Petrelintide (amylin analog, partnered with Zealand Pharma under the March 2025 up-to-$5.3 billion collaboration, Phase 3 monotherapy initiation planned late 2026 following ZUPREME-1's 10.7% weight loss at 42 weeks). Enicepatide (CT-388, dual GLP-1/GIP receptor agonist acquired from Carmot Therapeutics in 2023, 54% obesity resolution at 24 mg in Phase 2). HM17321 (urocortin-2 / CRFR2 receptor agonist peptide licensed from Hanmi Pharm on August 24, 2026 with $190 million upfront plus up to $2.3 billion in milestones plus tiered royalties). The Roche Pharma Day coincides with the EASD 2026 Annual Meeting Milan September 28 through October 2, where AstraZeneca will present AZD6234 Phase 2 data, Zealand Pharma will present petrelintide data, and Novo Nordisk will present amycretin and CagriSema updates.
Amylyx Pharmaceuticals (NASDAQ: AMLX) provided pre-launch commercial-readiness detail Tuesday September 1, 2026 as the company continues to advance toward NDA submission for avexitide (exendin-9-39, a GLP-1 receptor antagonist peptide) in post-bariatric hypoglycemia (PBH) following the August 18 Phase 3 LUCIDITY primary-endpoint hit (55% reduction in composite Level 2/3 hypoglycemic events, p=0.000003). Target NDA submission end of 2026; commercial launch preparation continues on schedule; and the company will use the upsized $500.2 million August 21 public offering to fund launch operations plus AMX0318 (long-acting follow-on peptide) IND-enabling studies. The Priority Review Voucher regime granted Arrowhead $215 million for plozasiran continues to shape the commercial economics of first-in-class peptide approvals in rare metabolic indications, and Amylyx is expected to be eligible if avexitide receives Breakthrough Therapy designation.
Following the August 22 Lancet Diabetes & Endocrinology publication of the full EECOH-2 Phase 3 trial results for Xianweida's ecnoglutide (XW003, a first-in-class cAMP-biased GLP-1 receptor agonist that preferentially activates the cAMP signaling pathway over β-arrestin recruitment), Chinese biotech peptide activity continued through end of August into September. Ecnoglutide received its Chinese NMPA approval for type 2 diabetes January 30, 2026, followed by the March 6, 2026 approval for weight management in adults with overweight or obesity; the Lancet publication supplies the peer-reviewed data package supporting global regulatory submissions. Ecnoglutide is licensed to Pfizer under the up-to-$495 million partnership announced in 2024 for ex-China commercialization. The biased-agonism concept (selective signaling pathway activation to separate efficacy from tolerability) is now being pursued by CSPC (SYH2069 GLP-1/GIP dual-biased agonist) and other Chinese biotech peptide developers.
Samsung Biologics (KRX: 207940), through its Swiss subsidiary Samsung Peptide AG, published Monday August 31, 2026 the formal tender offer prospectus for all publicly held registered shares of PolyPeptide Group AG (SIX: PPGN) on SIX Swiss Exchange. Terms: CHF 44.31 net in cash per share (implied equity value approximately CHF 1.46 billion / $1.8 billion, a 40% premium to the CHF 31.65 undisturbed share price of April 10, 2026). The cooling-off period runs 10 SIX trading days from September 1, and the main offer period commences September 15, 2026 through October 12, 2026 at 4 p.m. Swiss time. Draupnir Holding B.V. (approximately 55.65% of PolyPeptide shares) has committed to tender all shares. Closing conditions include a 66⅔% minimum acceptance threshold plus customary regulatory approvals; transaction close is targeted for end of 2026. Samsung intends to squeeze out remaining minorities and delist PolyPeptide post-close, integrating the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into the Incheon multi-modality biologics footprint.
Ascendis Pharma (NASDAQ: ASND) and BioMarin Pharmaceutical (NASDAQ: BMRN) announced Monday August 31, 2026 a binding term sheet for a global settlement and license agreement resolving all litigation and disputes related to YUVIWEL (navepegritide, TransCon C-type natriuretic peptide for achondroplasia and hypochondroplasia). Terms: BioMarin grants Ascendis a non-exclusive, worldwide, royalty-bearing license to continue researching, developing, manufacturing, and commercializing navepegritide-related products without restriction, and waives certain regulatory rights and exclusivities. Ascendis makes royalty payments to BioMarin of 20% on U.S. net sales and 18% on European Union, South Korea, and Brazil net sales from first commercial sale through May 20, 2030. BioMarin dismisses the pending U.S. International Trade Commission Section 337 investigation plus litigation in Brazil, Denmark, Germany, South Korea, and the U.S. Northern District of California. The settlement covers all current and potential YUVIWEL indications, including achondroplasia and hypochondroplasia, and removes the largest overhang on the Ascendis TransCon peptide platform.
Global Peptide Synthesis Market Outlook Report 2026-2035 was published August 31, 2026 via ResearchAndMarkets, projecting global peptide synthesis market growth from $4.4 billion in 2026 to $7.0 billion by 2035 (5.2% CAGR). Growth drivers: growing peptide therapeutics pipeline, rising demand for peptide active pharmaceutical ingredients, continued investment in manufacturing infrastructure, and increased outsourcing to specialized peptide CDMOs. Named anchor programs: CordenPharma more than EUR 900 million capacity investment; PolyPeptide doubling capacity at its Malmö site (in the context of the pending Samsung Biologics acquisition); Cambrex expanding its Waltham, Massachusetts facility. Regulatory context: authorities worldwide have approved nearly 100 peptide-based therapies across cancer, diabetes, chronic pain, HIV, multiple sclerosis, and osteoporosis. Report caveats: the top-line 5.2% CAGR reflects a broad market definition; a narrower peptide CDMO subsegment (Bachem, PolyPeptide, CordenPharma, AmbioPharm) is growing at 20%+ CAGR per multiple industry data sources given the incretin surge.
Roche (SIX: ROG) is scheduled to hold its Pharma Day investor event Monday September 28, 2026, providing updates across the R&D portfolio including three top-three-position obesity assets: petrelintide (amylin analog partnered with Zealand Pharma under the March 2025 up-to-$5.3 billion collaboration, ZUPREME-1 documented 10.7% weight loss at 42 weeks, Phase 3 monotherapy initiation planned late 2026); enicepatide (CT-388, dual GLP-1/GIP receptor agonist acquired from Carmot Therapeutics in 2023, 54% obesity resolution at 24 mg in Phase 2); and HM17321 (urocortin-2 / CRFR2 receptor agonist peptide licensed from Hanmi Pharm on August 24, 2026 with $190 million upfront plus up to $2.3 billion in milestones plus tiered royalties; Genentech takes over from Phase 2 forward). The Pharma Day briefing frames Roche as a credible third-place global obesity competitor behind Eli Lilly (Zepbound-Mounjaro-Foundayo plus upcoming retatrutide) and Novo Nordisk (Wegovy-Ozempic plus CagriSema plus amycretin), with EASD 2026 Milan September 28-October 2 the immediate downstream data catalyst.
Novartis (NYSE: NVS) reiterated at ESC Congress 2026 Saturday August 29 that it will advance the Phase 3 program for pacibekitug (an anti-IL-6 monoclonal antibody acquired from Tourmaline Bio through the $1.4 billion acquisition completed earlier in 2026) for cardiovascular risk reduction in inflammation-driven disease, notwithstanding the Phase 3 ZEUS trial failure of Novo Nordisk's ziltivekimab announced the same weekend. Novartis's stance is that ZEUS was underpowered in the specific ASCVD-plus-CKD-plus-inflammation subgroup rather than a class-level miss for IL-6 blockade, and that pacibekitug's differentiated pharmacokinetic profile (longer half-life and less frequent dosing) plus the differently-selected patient population in the planned Phase 3 will allow the mechanism to prove out. The commitment is a $1.4 billion acquisition-scale bet against the base-rate signal from ZEUS and continues the pattern of large pharma anti-inflammatory cardiovascular pipeline commitment following the earlier successful CANTOS canakinumab (IL-1β) proof of concept.
Takeda (NYSE: TAK) confirmed Sunday August 30, 2026 that commercial launch of Mimrylo (rusfertide, the first-in-class subcutaneous hepcidin mimetic peptide approved Friday August 28 for erythrocytosis in adults with polycythemia vera) is underway across the U.S., with the product available at specialty pharmacies within 48 hours of FDA approval. The commercial launch approach reflects Takeda's rare-blood-cancer specialty commercial infrastructure built up around Iclusig (ponatinib) for chronic myeloid leukemia and the recent Fruzaqla (fruquintinib) launch in colorectal cancer. Jefferies analyst projections of $2 billion peak sales assume rapid coverage decisions from major U.S. payers by end of 2026 plus European approval on the same clinical dataset in H1 2027. The Mimrylo launch establishes the hepcidin mimetic peptide category and sets a commercial template that Disc Medicine's DISC-0974 (an anti-hemojuvelin antibody targeting hepcidin from a different angle) and Silence Therapeutics' SLN124 (siRNA targeting TMPRSS6, an upstream hepcidin regulator) will need to differentiate against.
Protagonist Therapeutics (NASDAQ: PTGX) disclosed Friday August 28, 2026 that the Mimrylo FDA approval triggers $275 million in payments from Takeda, consisting of a $200 million opt-out fee (representing Protagonist's decision not to co-commercialize) and a separate $75 million approval milestone. The company retains additional undisclosed milestones and tiered royalties on rusfertide sales under the January 2024 worldwide license and collaboration agreement. Protagonist's platform-derived pipeline extends beyond rusfertide to include icotrokinra (an oral IL-23 receptor antagonist peptide licensed to Janssen, with a broad autoimmune-disease Phase 3 program) plus additional preclinical peptide programs across metabolic, inflammatory, and hematologic indications. The company's stock is expected to be one of the notable peptide-focused public-market performers of 2026 as rusfertide commercial ramp and icotrokinra Phase 3 readouts advance.
Quoin Pharmaceuticals (NASDAQ: QNRX) announced Friday August 28, 2026 a securities purchase agreement with new and existing healthcare-focused institutional investors (Sirenia Capital Management LP, Sphera Healthcare, AIGH Capital Management, Nantahala Capital, StemPoint Capital LP, and Stonepine Capital Management among others) for up to approximately $50.0 million in gross proceeds. Structure: approximately $30.8 million in initial upfront funding plus up to approximately $19.2 million from cash exercise of accompanying ordinary warrants. The private placement is expected to close on or about August 31, 2026. Proceeds will fund general corporate purposes including completion of clinical development of QRX003 (topical serine protease inhibitor) for Netherton Syndrome (a rare severe congenital ichthyosis caused by SPINK5 mutations that leaves affected patients with a defective skin barrier and life-threatening infections in infancy). Aggregate net proceeds (assuming full warrant exercise) are expected to fund Quoin into H2 2029.
H1 2026 GLP-1 franchise reporting places Eli Lilly (NYSE: LLY) tirzepatide (Mounjaro plus Zepbound) at nearly $27.7 billion in first-half revenue, an 88% year-over-year increase, versus Novo Nordisk (NYSE: NVO) semaglutide (Ozempic plus Wegovy plus Rybelsus plus Wegovy pill) at approximately $17.5 billion. The revenue gap between the two GLP-1 leaders has widened from under $2 billion at the same point last year to $10.2 billion, driven by Zepbound share gains in U.S. obesity following SURMOUNT-5 superiority data over Wegovy, Mounjaro upside in international markets (China +93% CER, Rest of World +136%), Foundayo (orforglipron) first commercial quarter contribution of $98 million, and semaglutide patent expiries approaching in select markets (generic Ozempic expected in Canada). Novo has cut 12,000 positions in H1 2026 and lowered gross margin outlook to 78%, while Lilly raised full-year 2026 revenue guidance to $85-87 billion.
AbCellera Biologics (NASDAQ: ABCL) announced Wednesday August 12, 2026 the pricing of an oversubscribed underwritten public offering of 17,435,897 common shares at $9.75 per share and pre-funded warrants to purchase up to 3,076,926 shares at $9.74999 per pre-funded warrant, for aggregate gross proceeds of approximately $200 million. Net proceeds of approximately $187 million are targeted to advance clinical development of lead program ABCL635 (an antibody-based candidate for vasomotor symptoms of menopause and related endocrine indications) plus additional immunology and oncology candidates. The offering closed August 14. AbCellera is a clinical-stage biotechnology company focused on discovering first-in-class antibody-based medicines in endocrinology, women's health, immunology, and oncology using its integrated antibody-discovery platform. Not a peptide company, but the offering is included here because AbCellera's platform overlaps with peptide-discovery approaches in the same discovery-to-clinical translation ecosystem, and the H2 2026 biotech financing window (which has already delivered Parabilis's $670M peptide IPO, Kardigan's $400M+ cardio IPO, and now AbCellera's $200M follow-on) reflects continued institutional appetite for platform-derived biologics.
Peptide CDMO announced investments have crossed $2.4 billion year-to-date in 2026, driven primarily by GLP-1 demand and a broadening pipeline of therapeutic peptides beyond the incretin class. Anchor programs: Samsung Biologics' CHF 1.46 billion / $1.8 billion all-cash tender offer for PolyPeptide Group AG (tender prospectus targeted for end-of-August publication, offer period September 15 to October 12); Bachem's more than CHF 500 million Sisslerfeld greenfield site collaboration in Switzerland (commercial production 2030) plus the recent Building K commercial GMP ramp; CordenPharma's confirmed $500 million Boulder expansion to 42,000+ liters by 2028 plus greater-than-€500 million greenfield near Basel; AmbioPharm's US-based supply scaling; and Lonza's SPPS capacity extensions. The global peptide CDMO market reached $4.59 billion in 2025 and is projected to reach $29.12 billion by 2035 (CAGR 20.3%) according to newly-published market research. The build-out is the binding upstream constraint on how much of the GLP-1, macrocyclic, and peptide-drug-conjugate pipeline reaches commercial scale.
Moderna (NASDAQ: MRNA) announced Thursday August 27, 2026 a private placement of $2 billion in convertible senior notes due 2032, with proceeds directed to the cancer vaccine business (led by intismeran autogene / mRNA-4157, the individualized neoantigen therapy that encodes up to 34 tumor-specific neoantigen peptides per patient) and to repay existing debt. The raise follows the Wednesday August 19 announcement that the Phase 3 INTerpath-001 melanoma trial of intismeran plus Keytruda met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival, which added roughly $44.5 billion in market cap to MRNA in a single session as shares surged 177%. Moderna is advancing intismeran in nine total Phase 2 and Phase 3 trials across melanoma, NSCLC, bladder cancer, and renal cell carcinoma, and the raise positions the company to accelerate manufacturing scale-out and expansion into new tumor types.
DualityBio (HKEX: 9606) announced Friday August 28, 2026 a global collaboration and license agreement with Genentech (Roche Group) to develop next-generation antibody-drug conjugates on DualityBio's proprietary DUPAC (DualityBio Unique Payload Antibody Conjugate) platform. Terms: $45 million upfront to DualityBio plus more than $1 billion in aggregate development, regulatory, and commercial milestone payments across all programs, with tiered royalties on annual net sales. DualityBio handles discovery through Phase Ia; Genentech takes over global clinical development and commercialization. The DUPAC platform is one of DualityBio's four proprietary ADC platforms and is dedicated to payloads with novel mechanisms of action designed to address resistance to existing topoisomerase inhibitor-based ADCs (Trodelvy, Enhertu, Datroway, and successors). The deal is Genentech's second Asia-based ADC alliance in a week and continues the pattern of large pharma buying diverse payload chemistries as ADC-first-line combinations expand.